$67M Raised by Cartography Biosciences for Oncology Bispecific; Nacuity’s NPI-001 Receives FDA Breakthrough Therapy Designation

$67 Million! Cancer-Fighting Bispecific Antibody Startup Completes Series B Financing

Today, Cartography Biosciences announced the completion of a $67 million Series B financing round.This round of financing was led by Pfizer Ventures, and the funds will be used to advance its core project CBI-1214 into clinical trials, with plans to initiate Phase 1 trial enrollment in early 2026.At the same time, the company will also use the funds obtained to accelerate the advancement of the next batch of differentiated oncology projects developed based on its proprietary ATLAS and SUMMIT drug discovery platforms.

CBI-1214 is a bispecific T-cell engager targeting LY6G6D, optimized for anti-tumor activity through protein engineering design.LY6G6D is considered an emerging and highly specific tumor antigen for the treatment of colorectal cancer (CRC). It is almost not expressed in healthy cells and is specifically expressed in the microsatellite stable (MSS) and low microsatellite instability (MSI-L) subtypes of CRC. These two types of patients account for the majority of CRC cases, representing a significant unmet medical need.

Innovative Small Molecule Drug Receives FDA Breakthrough Therapy Designation

Nacuity Pharmaceuticals announced today,NPI-001, a small molecule therapy independently developed by the company, has been granted Breakthrough Therapy Designation (BTD) by the U.S. FDA for the treatment of patients with retinitis pigmentosa (RP).The company stated that this designation will help accelerate the clinical development and regulatory communication process for NPI-001, advancing this novel therapeutic approach for RP more quickly into subsequent stages of development.

NPI-001 is a proprietary tablet based on N-acetylcysteine amide (NACA), designed to target oxidative stress mechanisms associated with diseases including RP. Preclinical studies have shown,NPI-001 can increase the levels of glutathione, the body's primary endogenous antioxidant, preventing highly reactive oxygen molecules from damaging retinal cells., thereby exerting potential retinal protectionFunctionAndInterventionDisease progression. In addition to BTD, NPI-001 has also been granted Fast Track and Orphan Drug designations by the FDA for the treatment of RP.

References:

[1] Nacuity Pharmaceuticals Granted U.S. FDA Breakthrough Therapy Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa. Retrieved October 2, 2025 from https://www.globenewswire.com/news-release/2025/10/02/3160415/0/en/Nacuity-Pharmaceuticals-Granted-U-S-FDA-Breakthrough-Therapy-Designation-for-NPI-001-N-acetylcysteine-amide-Tablets-for-the-Treatment-of-Retinitis-Pigmentosa.html

[2] Cartography Secures $67 Million Series B Financing to Advance Differentiated Oncology Pipeline of Antibody-Based Therapies into the Clinic. Retrieved October 2, 2025 from https://www.businesswire.com/news/home/20251002482177/en/Cartography-Secures-%2467-Million-Series-B-Financing-to-Advance-Differentiated-Oncology-Pipeline-of-Antibody-Based-Therapies-into-the-Clinic

Disclaimer: This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does WuXi AppTec support or oppose the views mentioned in the article. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: Individuals are welcome to share this article on their Moments. Unauthorized reproduction by media or organizations in any form to other platforms is prohibited. For authorization to reproduce, please reply "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain reprint guidelines.